Kymera Therapeutics to Report Second Quarter 2022 Results on August 9
July 27 2022 - 7:30AM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing targeted protein degradation to
deliver novel small molecule protein degrader medicines, will
report second quarter 2022 financial results on August 9, 2022 and
will host a conference call at 8:30 a.m. ET that day.
To access the conference call via phone, please dial
877-317-6789 (U.S.) or +1-412-317-6789 (International) and ask to
join the Kymera Therapeutics call. A live webcast of the event will
be available under “Events and Presentations” in the Investors
section of the Company’s website at www.kymeratx.com. A replay of
the webcast will be archived and available for one month following
the event.
About Kymera TherapeuticsKymera Therapeutics
(Nasdaq: KYMR) is a biopharmaceutical company pioneering the field
of targeted protein degradation, a transformative approach to
address disease targets and pathways inaccessible with conventional
therapeutics. Kymera’s Pegasus platform is a powerful drug
discovery engine, advancing novel small molecule therapies that
harness the body’s innate protein recycling machinery to degrade
dysregulated, disease-causing proteins. With a focus on undrugged
nodes in validated pathways, Kymera is advancing a pipeline of
novel therapeutics designed to address the most intractable
pathways and provide new treatments for patients. Kymera’s initial
programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or
JAK/STAT pathways, providing the opportunity to treat patients with
a broad range of immune-inflammatory diseases, hematologic
malignancies, and solid tumors. For more information, visit
www.kymeratx.com.
Founded in 2016, Kymera is headquartered in Watertown, Mass.
Kymera has been named a “Fierce 15” biotechnology company by Fierce
Biotech and has been recognized by the Boston Business Journal as
one of Boston’s “Best Places to Work.” For more information about
our people, science, and pipeline, please visit www.kymeratx.com or
follow us on Twitter or LinkedIn.
Investor Contact:Bruce Jacobs Chief Financial
Officer investors@kymeratx.com857-285-5300
Chris BrinzeyManaging Director,
Westwickechris.brinzey@westwicke.com339-970-2843
Media Contact:Todd
Cooper Senior Vice
President, Corporate Affairsmedia@kymeratx.com 857-285-5300
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jul 2023 to Jul 2024